ARTICLE | Finance
Ebb & Flow
October 29, 2007 7:00 AM UTC
Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of the multiple sclerosis drug were a "major disappointment."
The company didn't officially chalk up the shortfall to its competitive MS product Tysabri natalizumab, but it did warn that Tysabri could play a role in the future of the Avonex franchise...